iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares

iBio, Inc. (NASDAQ:IBIO) CFO Felipe Duran bought 24,835 shares of the business’s stock in a transaction on Thursday, March 19th. The shares were bought at an average cost of $2.02 per share, for a total transaction of $50,166.70. Following the completion of the acquisition, the chief financial officer directly owned 35,974 shares in the company, valued at approximately $72,667.48. This trade represents a 222.96% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

iBio Trading Up 5.7%

Shares of IBIO stock opened at $2.21 on Tuesday. The firm has a market capitalization of $76.33 million, a PE ratio of -2.21 and a beta of 1.18. The company has a 50-day moving average of $2.37. iBio, Inc. has a 1-year low of $0.56 and a 1-year high of $4.86.

iBio (NASDAQ:IBIO) last issued its quarterly earnings data on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

Hedge Funds Weigh In On iBio

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of iBio by 47.1% in the 4th quarter. Geode Capital Management LLC now owns 222,610 shares of the company’s stock valued at $430,000 after acquiring an additional 71,301 shares in the last quarter. Ameriprise Financial Inc. bought a new position in iBio during the third quarter worth $399,000. Marshall Wace LLP bought a new position in iBio during the fourth quarter worth $234,000. Cubist Systematic Strategies LLC acquired a new stake in iBio in the first quarter worth $224,000. Finally, Boothbay Fund Management LLC grew its holdings in iBio by 10.9% in the third quarter. Boothbay Fund Management LLC now owns 176,862 shares of the company’s stock worth $146,000 after purchasing an additional 17,414 shares during the period. 7.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $5.00 price target on shares of iBio in a research report on Wednesday, March 18th. Wall Street Zen cut shares of iBio from a “hold” rating to a “sell” rating in a research report on Saturday. Lifesci Capital raised shares of iBio to a “strong-buy” rating in a research note on Thursday, December 18th. JonesTrading assumed coverage on shares of iBio in a report on Tuesday, March 3rd. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iBio in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $4.75.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.